ADVANCED SOLID TUMOR

This early-phase study tests a new drug called PM54 in about 125 adults with advanced solid tumors that have not responded to standard treatments. The first part finds the safest dose by monitoring side effects; the second part checks how well the drug shrinks tumors. The goal is…

This early-stage study tests a new drug called IL12-L19L19 in people with advanced or spreading solid tumors that no longer respond to standard immunotherapy. The main goal is to find a safe dose and check for early signs that the drug shrinks tumors. About 80 adults aged 18 to 8…

This study tests two experimental drugs together in people with advanced solid tumors that have not responded to other treatments. The goal is to find safe doses and see if the combination can shrink tumors. About 210 adults will take part in this early-phase trial.

This early-stage study tests an experimental drug called MOMA-341, taken as a pill, for people with advanced solid tumors that have specific genetic features (MSI-H or dMMR). The study includes up to 132 adults whose cancer has not responded to prior treatments. The main goal is …

This study tests a new drug, YL242, alone or with other treatments, in people with advanced solid tumors that have not responded to prior therapy. The goal is to check safety, how the drug moves through the body, and whether it shrinks tumors. About 424 adults will take part acro…

This early-stage study tests a new drug called ISM6331 in people with advanced mesothelioma or other solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. About 100 adults w…

This study tests a new drug called GI-108 in people with advanced or metastatic solid tumors (cancers that have spread). The drug is designed to help the immune system fight cancer. The trial has two parts: first, finding a safe dose, and then seeing if it shrinks tumors. About 7…

This early-stage study tests a drug called nab-sirolimus in people with advanced solid tumors who also have moderate liver impairment. The goal is to find a safe dose and see how the body processes the drug. About 28 adults will take part, and the study is currently recruiting.

This early-phase study tests a new drug called BGB-43395, which blocks a protein (CDK4) that helps cancer cells grow. It is for people with advanced HR+/HER2- breast cancer or other solid tumors that have spread. The main goal is to find the safest and most effective dose, either…

This early-phase study tests a new drug called IPH5301 in people with advanced solid tumors that have spread. The drug works by blocking a protein (CD73) that tumors use to hide from the immune system. The study first finds the safest dose of IPH5301 alone, then tests it combined…

This study tests a new drug called PLX-61639 in adults with advanced solid tumors that have a specific genetic change (SMARCA4 mutation) and have stopped responding to standard treatments. The drug is taken daily by mouth and aims to shrink or control the cancer. The trial will e…

This study tests a new drug called GI-101, either alone or with pembrolizumab or lenvatinib, in people with advanced solid tumors (cancers that have spread). The goal is to see if it is safe and works against the cancer. About 317 adults with certain cancers like lung, kidney, or…

This early-phase study tests whether adding precise radiation to up to 10 tumor spots can improve the effectiveness of immunotherapy in people with advanced solid tumors that have spread to 3-10 places. About 28 adults will receive the combination and be monitored for changes in …

This early-stage study tests a treatment using a patient's own immune cells, called tumor-infiltrating lymphocytes (TILs), to fight advanced solid tumors. About 30 adults who have not responded to standard treatments will receive these cells along with chemotherapy. The main goal…

This early-phase trial tests an experimental drug called ALTA2618 in about 110 adults whose advanced solid tumors (including breast and endometrial cancers) have a specific AKT1 E17K gene mutation. The main goals are to check the drug's safety and find the right dose. Participant…

This early-stage trial tests a new drug called PTT-4256 in 30 adults with advanced solid tumors that have spread. The main goal is to check safety and find the best dose. Researchers will also look for early signs that the drug shrinks tumors or slows cancer growth.

This study tests a new drug called QLC5508, given together with other anti-cancer medicines, for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to find the safest dose and see if the combination can shrink tumors. About 444 adul…

This early-phase study tests a new drug called tolododekin alfa (ANK-101) for people with advanced solid tumors that have not responded to standard treatments. The drug is injected directly into tumors to see if it is safe and tolerable. About 97 adults with various solid cancers…

This study tests a new drug called WJB001 combined with other cancer treatments for people with advanced solid tumors. The goal is to find safe doses and see if the combination shrinks tumors. About 86 adults will take part in this early-phase trial.

This early-stage study tests a new drug called BMS-986500 in people with advanced solid tumors or breast cancer that has stopped responding to standard treatments. The main goal is to check safety and find the right dose. About 234 adults will take part, receiving the drug alone …

This early study tests a new drug, PEEL-224, for safety and how well it fights tumors in about 65 people with advanced solid tumors that have not responded to standard treatments. The goal is to find the best dose and see if the drug can shrink tumors. Participants must have good…

This early-phase study tests a new drug called AM-928, given as an IV infusion, in adults with advanced solid tumors that have not responded to standard treatments. The main goals are to find a safe dose and check for side effects. About 38 participants will receive different dos…

This study tests an experimental drug called STK-012, alone or with standard chemotherapy, in people with advanced solid tumors, especially a type of lung cancer called non-small cell lung cancer (NSCLC). The goal is to see if adding STK-012 helps shrink tumors better than standa…

This study tests a new drug called GTAEXS617 in people with advanced solid tumors that have not responded to standard treatments. The goal is to check the drug's safety, how the body processes it, and whether it can shrink tumors. About 230 adults with certain cancers like lung, …

This early-stage study tests a new drug called BG-75202, alone or with other treatments, in people with advanced breast cancer or other solid tumors that have stopped responding to standard care. The main goals are to check safety, find the right dose, and see if the drug shrinks…

This study tests a new drug, YL201, in people with advanced solid tumors that have not responded to other treatments. The trial has two parts: first, finding a safe dose, and second, testing how well it works in specific cancer types. About 312 adults will take part in China and …

This early-phase study tests a new drug, CLSP-1025, in adults with advanced solid tumors (like lung, colon, or pancreatic cancer) that have a specific genetic change called p53 R175H and a certain immune type (HLA-A*02:01). The goal is to find a safe dose and see if the drug can …

This study tests a new drug called ZGGS18 in people with advanced solid tumors that have not responded to standard treatments. The goal is to find a safe dose and see how well the drug is tolerated. About 222 participants will take part in this early-phase trial.

This study is for adults with advanced solid tumors who have run out of standard treatments. It tests a new drug called BNT3212, either alone or with another drug (pumitamig), to see if it is safe and can shrink tumors. The trial is in early phases (1 and 2) and will enroll about…

This study tests a new oral drug called ART6043, which blocks a DNA repair protein in cancer cells. It is given alone or with olaparib to adults with advanced or metastatic solid tumors that have not responded to other treatments. The goal is to see if it is safe and can shrink o…

This early-stage study tests a new drug, ASKC202, alone or with another drug (ASK120067), in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see if the drug shrinks tumors. About 150 adu…

This early-phase study tests a new drug called denikitug, alone or with another cancer drug (zimberelimab), in adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see if the drug shrinks tum…

This study tests a new drug, XTX301, in people with advanced solid tumors that have not responded to standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors. About 358 participants will take part in this early-phase trial across multiple centers…

This early-phase study tests a new drug called OMTX705, alone or with an immunotherapy, in people with advanced solid tumors that have not responded to standard treatments. The main goal is to check safety and find the best dose. About 150 adults with certain cancer types (like p…

This study tests an experimental oral drug called Alintegimod combined with standard immunotherapies (ipilimumab and nivolumab) in people with advanced solid tumors like melanoma, lung, kidney, or liver cancer who have already tried other treatments. The goal is to see if the com…

This study tests a new oral drug, VLS-1488, in people with advanced solid tumors that have not responded to other treatments. The goal is to find a safe dose and see if it can shrink tumors or slow cancer growth. About 200 adults with specific cancers like ovarian, lung, or breas…

This study tests a new drug called PC14586 (rezatapopt) in people with advanced or spreading solid tumors that have a specific change in the TP53 gene (Y220C mutation). The goal is to see if the drug is safe and works against these cancers. About 300 adults (and some teens after …

This early-stage trial tests an experimental drug, MRTX1719, in adults with advanced solid tumors that have a specific genetic change (loss of the MTAP gene). The study aims to find a safe dose and see if the drug can shrink tumors or slow their growth. About 336 participants wit…

This early-stage study tests a new drug, BNT317, in about 39 people with advanced solid tumors who have no other treatment options. The main goal is to check safety and find the best dose. Researchers will also look at how the drug works in the body and if it can shrink tumors.

This early-stage study tests a new drug called CHS-114 in people with advanced solid tumors that have stopped responding to standard treatments. The drug targets a protein on certain immune cells to help the body fight cancer. About 87 participants will receive the drug alone or …

This early-stage study tests a new drug called AXT-1003 in people with advanced non-Hodgkin lymphoma or solid tumors that have not responded to standard treatments. The main goal is to check safety and find the right dose. About 78 participants will be enrolled.

This study tests a new drug called BG-C0902 for people with advanced solid tumors that have not responded to other treatments. The drug is designed to attach to specific proteins on cancer cells and deliver a chemotherapy-like payload directly to them. The main goals are to check…

This early-stage study tests a new drug called PLB-002 in about 100 adults with advanced solid tumors that have not responded to other treatments. The main goals are to find the safest dose and understand side effects. PLB-002 is designed to attack cancer cells while sparing heal…

This early-phase study tests a new drug called INI-4001, alone or with standard immunotherapy, in people with advanced solid tumors that have spread. The main goal is to find a safe dose and check for side effects. About 50 adults with various cancers that cannot be cured with cu…

This study tests a new drug called LM-108, given with other cancer drugs (penpulimab and chemotherapy), in people with advanced solid tumors that have not responded to prior treatments. The goal is to find a safe dose and see if the combination can shrink tumors or delay their gr…

This early-stage study tests an experimental drug, LY4050784, in people with advanced solid tumors that have a specific change in the SMARCA4 gene. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. About 340 adults whose cancer ha…

This study tests a new drug called LM-24C5 in people with advanced solid tumors that have not responded to other treatments. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. About 49 adults will take part in this early-phase trial.

This early-stage study tests the safety of a new drug called ERX-315 in 15 adults with advanced solid tumors (such as breast, ovarian, or pancreatic cancer) that have stopped responding to approved therapies. The main goal is to find safe doses and watch for side effects, not to …

This early-stage study tests a new drug called M0324 in people with advanced solid tumors that have not responded to standard treatments. The drug is designed to target cancer cells and boost the immune system. Researchers will test M0324 alone, with another immunotherapy (pembro…

This study tests an experimental drug called CX-5461 in people with advanced solid tumors (like pancreatic, prostate, breast, or ovarian cancer) that have specific gene changes in BRCA2 or PALB2. The goal is to find a safe dose and see if the drug can shrink tumors or slow their …

This early-phase study tests a new oral drug, SW-682, in adults with advanced solid tumors that have not responded to standard treatments. The study focuses on cancers with specific genetic changes in the Hippo pathway. The goal is to find a safe dose and see if the drug can shri…

This study tests a new drug called AI-081 in people with advanced solid tumors that have spread or cannot be removed. The drug is designed to block two cancer growth signals (PD-1 and VEGF) at once. The trial aims to find the safest dose and check how well the drug works. About 3…

This study tests an experimental drug called BNT326 in people with advanced solid tumors that have spread or come back after other treatments. The goal is to find the best dose and see if it is safe and effective, both alone and when combined with other cancer immunotherapies. Ab…

This study tests a new drug called IPN01195 in adults with advanced solid tumors that have spread and no longer respond to standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors. About 85 participants will take the drug by mouth, and researcher…

This study tests a new drug called DS-3939a in people with advanced solid tumors that have spread or cannot be removed. The main goals are to check safety and find the right dose, and to see if the drug can shrink tumors. About 540 adults will take part across multiple centers.

This early-phase study tests a new drug called HCB101 in adults with advanced solid tumors or non-Hodgkin lymphoma that hasn't responded to standard treatments. The main goals are to check safety and find the right dose. About 80 participants will receive the drug through an IV t…

This study tests a new drug called ifinatamab deruxtecan in people with advanced solid tumors that have not been cured by other treatments. It is the first time this drug is being used in humans. The study has two parts: first, to find the safest dose, and second, to see how well…

This study tests a new oral drug, AVZO-021, in people with advanced solid tumors that have not responded to other treatments. The drug targets a protein called CDK2 to slow or stop cancer growth. The trial has two phases: first to find the safest dose, then to see if it shrinks t…

This early-phase study tests an oral drug called BB102 in people with advanced solid tumors that have not responded to standard treatments. The drug targets a protein (FGFR4) that can help tumors grow. The main goals are to check safety, find the best dose, and see if it shrinks …

This early-phase study tests a new experimental drug called JZP898, given alone or with the immunotherapy pembrolizumab, in adults with advanced or metastatic solid tumors that have not responded to standard treatments. The main goals are to check safety, find the right dose, and…

This early-stage study tests a new drug called MBS8(1V270) in about 106 people with advanced solid tumors that have not responded to standard treatments. The main goal is to check safety and find the best dose. Researchers will also look for early signs that the drug shrinks tumo…

This study tests a new drug called LY4052031 in people with advanced or spreading solid tumors, including bladder, breast, lung, and other cancers. The goal is to see if the drug is safe and works against these cancers. About 420 participants will take part, and the study will la…

This early-stage study tests a new cancer treatment called FT825, a type of CAR T-cell therapy that is made from donor cells and does not need to be personalized. It is given with or without additional antibody drugs to people with advanced solid tumors that have HER2 or other ma…

This study tests a new oral drug, HEC169096, that blocks a cancer-driving protein called RET. It is for people with advanced thyroid cancer, non-small cell lung cancer, or other solid tumors that have not responded to standard treatments. The trial has two phases: first to find t…

This early-phase study tests a new drug called GS-5319 in adults with advanced solid tumors that lack a gene called MTAP. The main goals are to check the drug's safety, find the best dose, and see how the body processes it. About 178 participants whose cancer has not responded to…

This study tests a new drug called IMP1734 in people with advanced solid tumors that have not responded to other treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. About 156 adults with certain breast, ovarian, or prost…

This study tests two experimental drugs, QLP2117 and QL2107, together in people with advanced solid tumors that have not responded to standard treatments. The goal is to see if the combination is safe and can shrink or control tumors. About 149 participants will receive the drugs…

This study tests a genetically modified, weakened bacteria (T3P-Y058-739) in about 100 adults with advanced solid tumors that have no standard treatment options. The bacteria is given alone or with the immunotherapy drug pembrolizumab, either as an injection into the tumor or int…

This early-stage study tests a new drug, ARC101, in about 70 people with advanced solid tumors that have not responded to other treatments. The main goal is to check the drug's safety and how the body processes it. Researchers will also look for signs that the drug shrinks tumors…

This study tests a new drug called LM-2417, alone or with other cancer treatments, in people with advanced solid tumors that have not responded to standard therapy. The main goals are to check safety, find the best dose, and see early signs of tumor shrinkage. About 320 adults ag…

This early-phase study tests whether a new drug, CHS-114, combined with the immunotherapy toripalimab (and possibly other standard treatments) is safe and can shrink tumors in people with advanced or metastatic solid tumors. About 154 adults whose prior treatments have stopped wo…

This study tests a new oral drug, AVZO-023, for people with advanced solid tumors, including a type of breast cancer (HR+/HER2-). The goal is to find the safest dose and see if it can shrink tumors. About 380 adults will take the drug alone or with other treatments.

This study tests an experimental drug called patritumab deruxtecan in people with advanced solid tumors that have spread or cannot be removed. The trial includes 740 participants with 13 different cancer types, such as lung, breast, and prostate cancer. The goal is to see if the …

This early-phase study tests a new drug called BG-68501 in people with advanced solid tumors (like breast, lung, or ovarian cancer) that have not responded to standard treatments. The goal is to find a safe dose and see if the drug shrinks tumors, either alone or combined with ot…

This study tests an experimental drug called HY05350 in people with advanced solid tumors that have a protein called MSLN. The goal is to find safe doses and see if the drug can shrink tumors. About 262 adults aged 18 to 75 who have not responded to standard treatments will take …

This early-phase study tests a new drug called GTB-5550 in adults with advanced solid tumors that have not responded to prior treatments. The drug is designed to bridge natural killer cells to cancer cells, helping the immune system attack the tumor. The main goal is to find the …

This early-phase study tests an experimental pill, NKT3964, designed to break down a protein (CDK2) that helps cancer cells grow. About 150 adults with advanced or metastatic solid tumors (including ovarian, endometrial, breast, gastric, and lung cancers) that have stopped respon…

This early-stage study tests a new drug called STX-001, given as an injection directly into tumors, either alone or with another drug (pembrolizumab). The goal is to see if it is safe and can shrink or control advanced solid tumors, including melanoma. About 108 adults with tumor…

This study tests a new drug called AU-007 in people with advanced solid tumors (like melanoma or lung cancer) that cannot be removed by surgery or have spread. The drug is designed to help the immune system fight cancer more effectively. About 159 participants will receive AU-007…

This early-stage study tests a new drug called TORL-1-23 in people with advanced solid tumors, including ovarian, endometrial, and lung cancers. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. About 90 participants will take part.

This early-phase study tests a new drug called BGB-B455 in people with advanced or metastatic solid tumors that have a specific protein (CLDN6). The main goals are to find the safest dose and understand side effects. About 90 participants will join, and the study has two parts: f…

This study tests a new drug called XL309, alone or with another drug (olaparib), in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see if the drug can shrink tumors. About 429 adults w…

This early-phase study tests a new drug called KK2269, given alone or with chemotherapy (docetaxel), in adults with advanced solid tumors that have not responded to standard treatments. The main goal is to check safety and find the right dose. About 101 people with certain cancer…

This study tests a modified salmonella bacteria (SGN1) that is injected directly into tumors. The bacteria are designed to grow inside the tumor and cut off its food supply (an amino acid called methionine), starving the cancer cells. The trial involves about 70 adults with advan…

This early-stage study tests a new drug called JMT106 in 200 adults with advanced solid tumors (such as lung or liver cancer) who have tried other treatments without success. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. Parti…

This study tests a combination of two experimental drugs, ZGGS18 and ZG005, in people with advanced solid tumors (cervical, liver, neuroendocrine, or lung cancer) who have run out of standard options. The main goals are to find a safe dose and see if the drugs can shrink tumors. …

This early-phase study tests a new drug called PYX-201 in people with advanced solid tumors that have come back or spread. The main goals are to find a safe dose and see if the drug can shrink tumors. About 330 adults with certain types of breast cancer, head and neck cancer, or …

This study tests a new drug called DB-1310 in people with advanced solid tumors that have not responded to standard treatments. The goal is to find a safe dose and see if it can shrink tumors. About 1,000 adults will take part in this early-phase trial.

This study is testing an experimental drug called BG-75098, given alone or with other medicines, in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors…

This study tests a new drug called raludotatug deruxtecan (R-DXd) in people with advanced or metastatic solid tumors that have not responded to other treatments. The goal is to see if the drug can shrink tumors or slow disease progression. About 200 adults will take part, and the…

This study tests a new drug called IPN01203 in about 102 adults with advanced solid tumors that have spread and stopped responding to standard immunotherapy. The goal is to find a safe and effective dose that can slow or stop tumor growth. Participants receive the drug and are mo…

This early-stage study tests a new drug called BG-T187, which is designed to attach to two cancer-related targets (EGFR and MET) to attack tumor cells. About 87 adults with advanced solid tumors that have not responded to prior treatments will receive the drug alone or with other…

This early-phase study tests a new drug called M3554 in people with advanced solid tumors, specifically soft tissue sarcoma and a type of brain cancer (glioblastoma). The main goal is to find a safe dose and check for side effects. About 52 participants will receive the drug intr…

This study is testing an experimental drug called MGC026 in about 250 adults with advanced solid tumors that have not responded to other treatments. The main goals are to check the drug's safety and find the right dose. Participants receive the drug by IV and are closely monitore…

This early-stage study tests a new medicine called SNV1521 in people with advanced solid tumors that have spread or cannot be removed. The main goals are to check if the drug is safe, tolerable, and to find the best dose. About 400 participants will receive different doses, and s…

This early-phase study tests an experimental oral drug called CID-078 in 220 adults with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if the drug is safe and can shrink tumors. It is a first-in-human trial, so the main focus is on …

This study tests a new drug called EP0031 in about 265 adults with advanced cancers (like non-small cell lung cancer) that have a specific RET gene change. The goal is to see if the drug is safe, what side effects it causes, and how well it shrinks tumors. Participants must have …

This early-phase study tests a new drug called SIBP-A13 in 144 adults with advanced solid tumors that no longer respond to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors or control the disease. Participants …

This early-stage study tests a new oral drug called APR-1051 in about 90 adults with advanced solid tumors that have not responded to other treatments. The main goal is to check the drug's safety and find the best dose, while also looking for signs that it might shrink tumors. Pa…

This early-phase study tests a new experimental drug called BGB-58067, alone or with other cancer treatments, in people with advanced solid tumors that have a specific genetic change (MTAP deficiency). The main goals are to check the drug's safety, find the best dose, and see if …

This early-stage study tests a new drug called SHR-1049 in 200 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. This is not a cure, but aims to con…

This early-phase study tests a new drug called ADCE-T02 in people with advanced solid tumors that have not responded to other treatments. The drug is designed to target and attack cancer cells while sparing healthy ones. The main goals are to find the safest dose and understand s…

This early-phase study tests an experimental drug called VAX014, which is injected directly into tumors to kill cancer cells. It is being studied alone and with standard immunotherapy drugs (nivolumab or pembrolizumab) in adults with advanced solid tumors who have tried other tre…

This study tests an experimental drug called JAB-23E73 in people with advanced solid tumors that have a KRAS gene change. The goal is to see if the drug is safe and can shrink tumors. About 334 adults will take part in two phases: first to find the right dose, then to measure how…

This early-phase study tests an oral gel called TRX-920 in people with advanced solid tumors that no longer respond to standard treatments. The gel contains a chemotherapy drug that aims to shrink tumors with fewer side effects than the standard IV version. About 30 participants …

This early-stage study tests a new drug, NXP900, in about 140 adults with advanced solid tumors (like lung, kidney, or mesothelioma) that have not responded to standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors. Participants will receive NX…

This early-phase study tests a new drug called PEP08 in people with advanced solid tumors that have a specific genetic change (MTAP deletion). The main goals are to check safety, find the right dose, and see if the drug shows signs of shrinking tumors. About 40 adults who have tr…

This study tests a new drug called OBI-902 in people with advanced solid tumors that have not been cured by standard treatments. The trial has three parts: first, finding a safe dose; second, checking how well that dose works in certain cancers; and third, comparing different dos…

This study tests a modified Salmonella bacteria (SGN1) designed to grow inside tumors and cut off their food supply. About 70 adults with advanced solid tumors that have not responded to standard therapy will receive the treatment. The main goals are to check safety and see if th…

This study tests a new treatment plan for people with locally advanced rectal cancer. Participants first get a short course of radiation along with an immune-boosting drug (IL-2). Then they receive chemotherapy (CAPOX) plus two immunotherapy drugs (a PD-1 antibody and IL-2). The …

This early-phase study tests a new drug called BG-C0979, alone or with another drug (tislelizumab), in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see if the drug shrinks tumors. Abo…

This early-stage study tests a new drug called ABL103 in adults with advanced solid tumors that have stopped responding to standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors. About 96 participants will receive the drug intravenously, and re…

This early-phase study tests a new drug called HCB301 in 50 adults with advanced solid tumors or Hodgkin lymphoma that has come back or not responded to other treatments. The main goals are to check safety, find the right dose, and see if the drug can shrink tumors. Participants …

This early-phase study tests a new drug that delivers radiation directly to cancer cells in people with advanced solid tumors (like lung, colon, head and neck, pancreatic, stomach, or kidney cancer) that have stopped responding to standard treatments. The main goals are to check …

This early-stage study tests a new drug called AN4005 in about 31 adults with advanced solid tumors or lymphoma that has not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see how the body processes it. Participants will r…

This study tests a new drug called SHR-4375 combined with other cancer treatments in 198 adults with advanced solid tumors that have not responded to standard care. The goal is to find safe doses and see if the combination can shrink tumors or slow their growth. Participants must…

This early-phase study tests an experimental drug called lunresertib, given alone or with other drugs, in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to check safety, find the best dose, and see if the drug can shrink …

This early-phase trial tests a new drug called XB628 in about 75 people whose advanced solid tumors have not responded to standard treatments. XB628 is designed to help the body's natural killer cells attack cancer cells more effectively. The main goals are to check safety and fi…

This early-stage trial tests a new drug called DS5361b, alone or with another drug (pembrolizumab), in adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. Ab…

This early-stage study tests a new drug called SIBP-A17 in people with advanced solid tumors who have no other treatment options. The main goal is to check the drug's safety, find the best dose, and see how the body processes it. About 196 adults aged 18 to 75 will take part.

This early-phase study tests an experimental drug called BGB-26808, either alone or combined with an immunotherapy (tislelizumab), in people with advanced solid tumors that have stopped responding to standard treatments. The main goal is to find the safest and most effective dose…

This early-stage study tests an experimental drug called VSV-02 in 6 adults with advanced solid tumors (like melanoma, breast, or lung cancer) who have run out of standard options. The drug is given both into a vein and directly into the tumor to see if it can shrink or control t…

This early-phase study tests a new oral drug, DO-2, in adults with advanced solid tumors (like lung cancer) that have a specific MET gene change and no standard treatment options left. The main goal is to check the drug's safety and find the right dose. About 55 participants will…

This early-phase study tests a new drug, YL217, in about 220 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to find a safe dose and check for side effects, while also seeing if the drug can shrink tumors. Participants must be …

This early-stage study tests a new drug called ONC-841 in about 72 people with advanced solid tumors that have spread. The main goals are to check safety, find the best dose, and see if it helps control the cancer. Participants receive the drug through an IV, either alone or with…

This early-phase study tests a new drug called BG-C137 in people with advanced solid tumors that have not responded to standard treatments. The drug is designed to deliver a cancer-killing agent directly to cells with a specific marker (FGFR2b). The main goals are to check safety…

This study tests whether combining two drugs, afatinib and pemigatinib, is safe and can shrink tumors in people with advanced solid cancers that have certain genetic changes (FGFR alterations). About 70 adults whose standard treatments have stopped working will take part. The mai…

This study tests a new drug called BG-C9074, which is designed to attach to a protein on cancer cells and deliver a toxic payload. The trial is for people with advanced solid tumors that have not responded to standard treatments. The goal is to find the safest dose and see if the…

This study tests an experimental drug called HH2853 for people with certain types of blood cancer (non-Hodgkin's lymphoma) or advanced solid tumors that have come back or not responded to treatment. The goal is to find the safest dose and see if the drug can shrink tumors. About …

This early-stage clinical trial is testing a new drug called CLIO-8221 in people with advanced solid tumors that have spread or cannot be removed by surgery. The study aims to find the safest and most effective dose and get early signs of whether the drug helps control the cancer…

This is the first study in people testing a new antibody drug called NTX-1088, which targets a protein found on many cancer cells. The trial will test the safety of NTX-1088 given alone and in combination with an existing immunotherapy drug (pembrolizumab) in 90 patients with adv…

This is a first-in-human study to test the safety and find the right dose of a new drug called BAL0891. It will be given alone and in combination with other cancer drugs to 260 adults with advanced solid tumors (like certain breast and stomach cancers) or a type of leukemia that …

This study tests a new imaging agent (89Zr-DFO-REGN5054) that may show where immune cells are active in tumors. About 50 adults with advanced solid cancers will receive the agent and a PET scan, along with the immunotherapy cemiplimab. The goal is to check safety and see if the s…

This study tests a new radioactive tracer called 64Cu-GRIP B that lights up immune activity in PET scans. It aims to see if the tracer is safe and can help detect which advanced cancers (like prostate, kidney, or bladder) are more likely to respond to immunotherapy. About 91 adul…

This early-phase study is testing whether adding metformin (a common diabetes medicine) to standard chemotherapy or immunotherapy is safe for people with advanced solid tumors. About 60 adults will take metformin alone for two weeks, then continue it alongside their regular cance…

This study monitors patients who have already received at least one dose of Replimune's experimental cancer therapy (RPx) for up to 5 years. The goal is to identify any delayed side effects or infections related to the treatment. No new drugs are given—participants simply provide…

This study looks at the genetic makeup of tumors from 40 adults with advanced solid tumors or lymphoma. The goal is to use this information to better match patients with early phase clinical trials. Participants provide a tissue sample from a past surgery or biopsy, but no new tr…

This study tests whether a special clinic that checks your genes and all your medications can lower the risk of harmful drug interactions. About 1,300 adults with cancer or mental health conditions who take multiple drugs will get a consultation. The goal is to help doctors presc…